Combination Therapies and Uses for Treatment of Demyelinating Disorders
AssigneeBiogen MA Inc.
InventorsDiego Cadavid, Sha Mi
Life of this patent
Estimating the term…
Abstract
Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.
Claims34
A method of treating a CNS demyelinating disease chosen from multiple sclerosis or an inflammatory condition of the optic nerve, in a subject in need thereof, said method comprising administering to the subject an anti-LINGO-1 antibody molecule and an immunosuppressive agent in an amount sufficient to treat the CNS demyelinating disease, wherein the immunosuppressive agent is chosen from one or more of:
- an IFN-β 1 molecule;
- a corticosteroid;
- a polymer of glutamic acid, lysine, alanine and tyrosine or glatiramer;
- an antibody or fragment thereof against alpha-4 integrin or natalizumab;
- an anthracenedione molecule or mitoxantrone;
- a fingolimod or FTY720 or other S1P1 functional modulator;
- a dimethyl fumarate;
- an antibody to the alpha subunit of the IL-2 receptor of T cells or daclizumab;
- an antibody against CD52 or alemtuzumab;
- an antibody against CD20;
- or
- an inhibitor of a dihydroorotate dehydrogenase or teriflunomide;
- thereby treating the CNS demyelinating disease.
-4. (canceled)
-7. (canceled)
-17. (canceled)
-20. (canceled)
-27. (canceled)
(canceled)
-36. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-54. (canceled)
-58. (canceled)
A packaged composition comprising an antibody molecule against human LINGO-1 and an IFN-β 1 molecule with instructions for use in treating multiple sclerosis or an inflammatory condition of the optic nerve.
A method of treating acute optic neuritis, in a subject in need thereof, said method comprising administering to the subject an anti-LINGO-1 antibody molecule in an amount sufficient to treat the acute optic neuritis.
-65. (canceled)
Dependencies are inferred from the claim text.